OncoMatch/Clinical Trials/NCT04084496
mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
Is NCT04084496 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Folfirinox for pancreatic cancer.
Treatment: Folfirinox — Although FOLFIRINOX regimen was recently presented to be effective as adjuvant chemotherapy for resectable pancreatic cancer in selected patients who have good physical condition, there is still insufficient evidence on this regimen in treating resectable pancreatic cancer patients in China. Since for many tumors, different races may show different responses to the same regimen, we design this open phase Ⅱ study to evaluate the the efficacy and safety of mFOLFIRINOX as adjuvant chemotherapy for resectable pancreatic cancer in China.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: surgery — curative (radical resection)
Receive radical resection of pancreatic cancer
Cannot have received: cytostatic chemotherapy
No prior cytostatic chemotherapy
Cannot have received: antineoplastic agent
Patient is concurrently using other antineoplastic agent
Cannot have received: investigational antineoplastic agent
Patient has used investigational antineoplastic agent within 4 weeks prior to entry.
Lab requirements
Blood counts
ANC ≥ 2.0 x 10^9/L; Platelets ≥ 90 x 10^9/L; Hemoglobin ≥ 90 g/L
Kidney function
Creatinine ≤ 1.25 times ULN
Liver function
AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is liver metastasis); Serum bilirubin ≤ 1.2 x ULN
Patient has adequate bone marrow and organ function. Absolute Neutrophil Count (ANC) ≥ 2.0 x 10^9/L Platelets ≥ 90 x 10^9/L Hemoglobin ≥ 90 g/L. Patient has adequate liver function AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is liver metastasis) Serum bilirubin ≤ 1.2 x ULN Creatinine ≤ 1.25 times ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify